RTP Mobile Logo
Select Publications

Assouline S et al. Mosunetuzumab shows promising efficacy in patients with multiply relapsed follicular lymphoma: Updated clinical experience from a phase I dose-escalation trial. ASH 2020;Abstract 702.

Belada D et al. A phase 1b, open-label, randomized study to assess safety and preliminary efficacy of tafasitamab (MOR208) or tafasitamab + lenalidomide in addition to R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma: Analysis of the safety run-in phase. ASH 2020;Abstract 3028.

Epstein-Peterson ZD et al. Frontline sequential immunochemotherapy plus lenalidomide for mantle cell lymphoma incorporating MRD evaluation: Phase II, investigator-initiated, single-center study. ASH 2020;Abstract 119.

Gritti G et al. Polatuzumab vedotin plus venetoclax with rituximab in relapsed/refractory diffuse large B-cell lymphoma: Primary efficacy analysis of a phase Ib/II study. ASH 2020;Abstract 599.

Herrera A et al. Consolidation with nivolumab and brentuximab vedotin after autologous hematopoietic cell transplantation in patients with high-risk Hodgkin lymphoma. ASH 2020;Abstract 472.

Jacobson C et al. Primary analysis of Zuma-5: A phase 2 study of axicabtagene ciloleucel (axi-cel) in patients with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL). ASH 2020;Abstract 700.

Leonard J et al. A phase 1b/3 randomized, double-blind, 3-stage study of tazemetostat or placebo plus lenalidomide and rituximab in patients with relapsed/refractory follicular lymphoma. ASH 2020;Abstract 2052.

Maddocks K et al. Long-term subgroup analyses from L-MIND, a phase 2 study of tafasitamab (MOR208) combined with lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma. ASH 2020;Abstract 3021.

Maloney D et al. Matching-adjusted indirect comparison (MAIC) of lisocabtagene maraleucel (liso-cel) vs axicabtagene ciloleucel (axi-cel) and tisagenlecleucel in relapsed/refractory (R/R) large B‐cell lymphoma (LBCL). ASH 2020;Abstract 2116.

Puckrin R et al. Lack of effectiveness of intravenous high-dose methotrexate for prevention of CNS relapse in patients with high-risk DLBCL: A retrospective analysis from Alberta, Canada. ASH 2020;Abstract 477.

Ruan J et al. Multi-center phase II study of oral azacitidine (CC-486) plus CHOP as initial treatment for peripheral T-cell lymphoma (PTCL). ASH 2020;Abstract 40.

Salles G et al. Analyzing efficacy outcomes from the phase 2 study of single-agent tazemetostat as third-line therapy in patients with relapsed or refractory follicular lymphoma to identify predictors of response. ASH 2020;Abstract 2047.

Seymour E et al. Selinexor in combination with R-CHOP for frontline treatment of non-Hodgkin lymphoma: Results of a phase 1b study. ASH 2020;Abstract 2109.

Straus D et al. Brentuximab vedotin with chemotherapy for patients with previously untreated, stage III/IV classical Hodgkin lymphoma: 5-year update of the ECHELON-1 study. ASH 2020;Abstract 2973.

Wang M et al. One-year follow-up of ZUMA-2, the multicenter, registrational study of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma. ASH 2020;Abstract 1120.

Wang ML et al. LOXO-305, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma, Waldenström’s macroglobulinemia, and other non-Hodgkin lymphomas: Results from the phase 1/2 BRUIN study. ASH 2020;Abstract 117.

Yasenchak C et al. Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients. ASH 2020;Abstract 471.